| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier-Free | NBP2-35015-10ug | |||
| Carrier-Free | NBP2-35015-1mg | |||
| Carrier-Free | NBP2-35015-500ug | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier-Free | NBP2-35257-10ug | |||
| Carrier-Free | NBP2-35257-1mg | |||
| Carrier-Free | NBP2-35257-500ug | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier-Free | NBP2-35078-1mg | |||
| Carrier-Free | NBP2-35078-100ug | |||
| Carrier-Free | NBP2-35078-500ug | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Azide and BSA Free | NBP2-75193-0.025mg | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Azide and BSA Free | NBP2-52687-0.025mg | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Azide and BSA Free | NBP2-75908-0.025mg | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Azide and BSA Free | NBP3-12021-0.025mg | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Azide and BSA Free | NBP2-52679-0.025mg | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Azide and BSA Free | NBP2-81270SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP2-50475-0.025ml | |||
![SDS-Page: Human IL-10 Protein [NBP2-35015]](http://images.novusbio.com/fullsize/Human-IL-10-Protein-SDS-Page-NBP2-35015-img0001.jpg "SDS-Page: Human IL-10 Protein [NBP2-35015]")
![SDS-Page: Rat IL-9 Protein [NBP2-35257]](http://images.novusbio.com/fullsize/Rat-IL-9-Protein-SDS-Page-NBP2-35257-img0001.jpg "SDS-Page: Rat IL-9 Protein [NBP2-35257]")
![SDS-Page: Human TNF-alpha His (N-Term) Protein [NBP2-35078]](http://images.novusbio.com/fullsize/Human-TNF-alpha-His-N-Term-Protein-SDS-Page-NBP2-35078-img0001.jpg "SDS-Page: Human TNF-alpha His (N-Term) Protein [NBP2-35078]")
![Immunofluorescence: IL6R Antibody (rhPM-1 (Tocilizumab)) - Chimeric [NBP2-75193] - Immunofluorescence staining of fixed U937 cells with anti-IL-6 receptorantibody rhPM-1 (Tocilizumab). Immunofluorescence analysis of paraformaldehyde fixed U937 cells on coverslips, permeabilized with 0.15% Triton and stained with the chimeric rabbit IgG version of rhPM-1 (Tocilizumab) (NBP2-75193) at 10 ug/ml for 1h followed by Alexa Fluor 488 secondary antibody (1 ug/ml), showing membrane staining. The nuclear stain is DAPI (blue). Panels show from left-right, top-bottom NBP2-75193, DAPI, merged channels and an isotype control. The isotype control was stained with an anti-Fluorescein antibody followed by Alexa Fluor 488 secondary antibody.](http://images.novusbio.com/fullsize/IL6R-Antibody-rhPM-1-Tocilizumab-Chimeric-Immunofluorescence-NBP2-75193-img0001.jpg "Immunofluorescence: IL6R Antibody (rhPM-1 (Tocilizumab)) - Chimeric [NBP2-75193] - Immunofluorescence staining of fixed U937 cells with anti-IL-6 receptorantibody rhPM-1 (Tocilizumab). Immunofluorescence analysis of paraformaldehyde fixed U937 cells on coverslips, permeabilized with 0.15% Triton and stained with the chimeric rabbit IgG version of rhPM-1 (Tocilizumab) (NBP2-75193) at 10 ug/ml for 1h followed by Alexa Fluor 488 secondary antibody (1 ug/ml), showing membrane staining. The nuclear stain is DAPI (blue). Panels show from left-right, top-bottom NBP2-75193, DAPI, merged channels and an isotype control. The isotype control was stained with an anti-Fluorescein antibody followed by Alexa Fluor 488 secondary antibody.")
![Flow Cytometry: OX40 Ligand/TNFSF4 Antibody (R4930 (Oxelumab)) - Chimeric [NBP2-52687] - Human peripheral blood leukocytes were fixed using 2% PFA, permeabilised using 0.5% Triton and stained with unimmunized rabbit IgG antibody (isotype control, black line) or the rabbit IgG-chimeric version of R4930 (NBP2-52687, blue line) at a dilution of 1:100 for 1h at RT. After washing, bound antibody was detected using a goat anti-rabbit IgG AlexaFluor 488 antibody at a dilution of 1:1000 and cells analyzed using a FACSCanto flow-cytometer.](http://images.novusbio.com/fullsize/OX40-Ligand-TNFSF4-Antibody-R4930-Oxelumab-Chimeric-Flow-Cytometry-NBP2-52687-img0001.jpg "Flow Cytometry: OX40 Ligand/TNFSF4 Antibody (R4930 (Oxelumab)) - Chimeric [NBP2-52687] - Human peripheral blood leukocytes were fixed using 2% PFA, permeabilised using 0.5% Triton and stained with unimmunized rabbit IgG antibody (isotype control, black line) or the rabbit IgG-chimeric version of R4930 (NBP2-52687, blue line) at a dilution of 1:100 for 1h at RT. After washing, bound antibody was detected using a goat anti-rabbit IgG AlexaFluor 488 antibody at a dilution of 1:1000 and cells analyzed using a FACSCanto flow-cytometer.")
![SDS-Page: Recombinant Rat IL-10 Protein [NBP2-61341]](http://images.novusbio.com/fullsize/Recombinant-Rat-IL-10-Protein-SDS-Page-NBP2-61341-img0002.jpg "SDS-Page: Recombinant Rat IL-10 Protein [NBP2-61341]")
![Flow Cytometry: IL-9 Antibody (D9302C12) - Chimeric [NBP3-12021] - Mouse splenocytes were stimulated with PMA and Ionomycin in presence of Monensin for 4 hours. The cells were fixed using 2% PFA, permeabilized using 0.5% Triton and stained with anti-Fluorescein IgG antibody (4-4-20; isotype control, black line) or the rabbit IgG version of D9302C12 (NBP3-12021, blue line) at a dilution of 1:100 for 1h at RT. After washing, bound antibody was detected using a goat anti-mouse IgG AlexaFluor(R) 488 antibody at a dilution of 1:1000 and cells were analyzed using a FACSCanto flow-cytometer.](http://images.novusbio.com/fullsize/IL-9-Antibody-D9302C12-Chimeric-Flow-Cytometry-NBP3-12021-img0001.jpg "Flow Cytometry: IL-9 Antibody (D9302C12) - Chimeric [NBP3-12021] - Mouse splenocytes were stimulated with PMA and Ionomycin in presence of Monensin for 4 hours. The cells were fixed using 2% PFA, permeabilized using 0.5% Triton and stained with anti-Fluorescein IgG antibody (4-4-20; isotype control, black line) or the rabbit IgG version of D9302C12 (NBP3-12021, blue line) at a dilution of 1:100 for 1h at RT. After washing, bound antibody was detected using a goat anti-mouse IgG AlexaFluor(R) 488 antibody at a dilution of 1:1000 and cells were analyzed using a FACSCanto flow-cytometer.")
![SDS-Page: Recombinant Human Lymphotoxin-alpha/TNF-beta Protein [NBP2-61307]](http://images.novusbio.com/fullsize/Recombinant-Human-Lymphotoxin-alpha-TNF-beta-Protein-SDS-Page-NBP2-61307-img0002.jpg "SDS-Page: Recombinant Human Lymphotoxin-alpha/TNF-beta Protein [NBP2-61307]")
![Western Blot: CCR4 Antibody (KW-0761 (Mogamulizumab)) - Chimeric [NBP2-81270] - Western Blot using CCR4 Antibody (KW-0761 (Mogamulizumab)) [NBP2-81270]. Human brain cerebellum (A) and human heart (B) lysates (35ug protein in RIPA buffer) were resolved on a 10% SDS PAGE gel and blots probed with the chimeric rabbit IgG version of KW-0761 [NBP2-81270] at 2 ug/ml before detection using an anti-rabbit secondary antibody. A primary incubation of 1h was used and protein was detected by chemiluminescence. The expected running size for CCR4 is 37.7kDa.](http://images.novusbio.com/fullsize/CCR4-Antibody-KW-0761-Mogamulizumab-Chimeric-Western-Blot-NBP2-81270-img0001.jpg "Western Blot: CCR4 Antibody (KW-0761 (Mogamulizumab)) - Chimeric [NBP2-81270] - Western Blot using CCR4 Antibody (KW-0761 (Mogamulizumab)) [NBP2-81270]. Human brain cerebellum (A) and human heart (B) lysates (35ug protein in RIPA buffer) were resolved on a 10% SDS PAGE gel and blots probed with the chimeric rabbit IgG version of KW-0761 [NBP2-81270] at 2 ug/ml before detection using an anti-rabbit secondary antibody. A primary incubation of 1h was used and protein was detected by chemiluminescence. The expected running size for CCR4 is 37.7kDa.")